PEC (6446) reported revenue of NT$2.84 billion for Oct 2026, +102.0% year on year and +7.6% from the previous month. Revenue for Jan–Oct 2026 was NT$22.57 billion (+85.7% year on year).
Revenue for Oct 2026 was a record high (previous high: Sep 2026, NT$2.64 billion). →
Year-on-year revenue growth: 25+ months in a row. →
In Oct 2026, it ranked No. 1 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$2.84 billion | +102.0% | +7.6% |
| Sep 2026 | NT$2.64 billion | +100.0% | +0.7% |
| Aug 2026 | NT$2.62 billion | +105.4% | +4.4% |
| Jul 2026 | NT$2.51 billion | +92.6% | +7.5% |
| Jun 2026 | NT$2.33 billion | +94.9% | -5.1% |
| May 2026 | NT$2.46 billion | +108.5% | +19.1% |
| Apr 2026 | NT$2.06 billion | +68.3% | +6.4% |
| Mar 2026 | NT$1.94 billion | +64.4% | +21.2% |
| Feb 2026 | NT$1.6 billion | +56.7% | +1.2% |
| Jan 2026 | NT$1.58 billion | +49.8% | -17.8% |
| Dec 2025 | NT$1.92 billion | +69.9% | +23.8% |
| Nov 2025 | NT$1.55 billion | +53.0% | +10.6% |
| Oct 2025 | NT$1.4 billion | +53.6% | +6.5% |
| Sep 2025 | NT$1.32 billion | +41.3% | +3.4% |
| Aug 2025 | NT$1.27 billion | +41.3% | -2.1% |
| Jul 2025 | NT$1.3 billion | +48.0% | +8.8% |
| Jun 2025 | NT$1.2 billion | +41.1% | +1.5% |
| May 2025 | NT$1.18 billion | +49.2% | -3.8% |
| Apr 2025 | NT$1.23 billion | +83.7% | +3.9% |
| Mar 2025 | NT$1.18 billion | +111.5% | +15.5% |
| Feb 2025 | NT$1.02 billion | +73.8% | -3.2% |
| Jan 2025 | NT$1.06 billion | +107.9% | -6.8% |
| Dec 2024 | NT$1.13 billion | +67.8% | +11.5% |
| Nov 2024 | NT$1.02 billion | +138.9% | +11.0% |
| Oct 2024 | NT$914.3 million | +67.0% | -1.9% |
Jan–Oct 2026 cumulative: NT$22.57 billion (+85.7% YoY)
Other Biotech & Medical companies
Compare with peers: PEC vs Lotus Pharm / PEC vs Bora / PEC vs Great Tree Pharmacy
| Company | Revenue | YoY |
|---|---|---|
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
| GKB | NT$748.3 million | -30.8% |
Company remark (original Chinese)
本月及本年累計營收較去年成長,主要來自認列美國子公司PharmaEssentia USA Corp.之營收。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16